Rapamycin (Sirolimus)

Pfizer辉瑞授权 目录号:S1039 别名: AY 22989,NSC-2260804

Rapamycin (Sirolimus) Chemical Structure

Molecular Weight(MW): 914.18

Rapamycin (Sirolimus)是一种特定的 mTOR 抑制剂,在 HEK293细胞中,IC50 为 ~0.1 nM。

规格 价格 库存 购买数量  
RMB 2501.99 现货
RMB 580.39 现货
RMB 2216.87 现货
RMB 5501.68 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户购买Selleck的此次产品后发表的文献64篇:

客户使用该产品的13个实验数据:

  • Protein blots showing MYC expression in naive and persister cells after 3 d of treatment with 2 uM AKT inhibitor MK-2206 (AKTi) or 10 nM mTOR inhibitor rapamycin (Rapa).

    Nat Genet 2014 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck.

    Cooperative Effects of AR and mTOR Inhibition In Vitro and In Vivo (A) In vitro response of Pten null;Ar+ murine (CaP8) and human (LNCaP) prostate cancer cells to AR knockdown (sh-AR) or pharmacological inhibition of AR (MDV3100, 10 nM) with and without rapamycin (R: 1 nM) treatment (Sc, control sh oligo). (B and D) In vivo response to treatments with castration, MDV3100, rapamycin, or their combinations as measured by cell proliferation (Ki67+cells) and (C and D) tumor burden in Pb-Cre+;-PtenL/L and Pb-Cre+;PtenL/L:ArL/Y mutants. Scale bars represent 2 mm (C), 200 mm (D), and 75 mm (D, inset). Error bars represent mean ±SD.

    Cancer Cell 2011 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck.

  • 48 hours after addition of rapamycin(150 nM), the cells were imaged as described in Figure A to detect formation of punctuated GFP-LC3 structure. Quantification represented the ratio of GFP-LC3 punctuated positive cell to the total cell counted(Figure B).

    Cell Res 2012 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck.

    H4-LC3-GFP cells were treated with 1 nM IFNA2 for the indicated periods in the presence of 200 nM rapamycin. Images of the cells were collected using an ArrayScan HCS 4.0 Reader. Representative cells are shown. The average spot intensity in 500 cells from each indicated sample was determined. Data are displayed as means ?SD of the spot intensity per cell (below). RLU, relative leight unit.

    Autophagy 2015 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck.

  • Rheb Induces Phospho-eIF2a Independent of mTORC1 and Promotes Phospho-eIF2a Predominantly through PERK (A) Western blotting of indicated proteins of HEK293 expressing cDNAs of myc (control) or myc-Rheb WT were grown in DMEM with serum (+) or without serum (-) or pretreated with the inhibitors rapamycin (250 nM) or DMSO (0.5%, control). (B) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with rapamycin or DMSO as in (A). (C) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with inhibitors of MAPK (PD98059, 50 mM) or PI3K (wortmannin, 100 nM), rapamycin, or DMSO.

    Cell Rep 2015 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck.

    Cells were cultured with the indicated concentrations of PLS-123, rapamycin (Granta519 0.002 μM, Mino 0.001 μM, Z138 0.005 μM), and their combination for 48 h. The results are expressed as the mean of relative activity and S.D. from triplicate cultures. The results are representative of at least three similar experiments.

    Int J Cancer, 2018, 142(1):202-213. Rapamycin (Sirolimus) purchased from Selleck.

  • Rapamycin (RPM) inhibits OA-induced lipogenesis. Male SD rats were divided into three groups, and then treated as follows for seven days: group I (control; Ctrl), normal diet + vehicle; group II (OA), 1% OA diet + vehicle; group III (OA + RPM), 1% OA diet + RPM. (A) Hepatic TG concentrations were determined using the serum triglyceride determination kit. (B) Fixed liver sections were subjected to HE and Oil Red O staining as well as immunohistochemistry assays with SREBP-1 antibody. Representative microphotographs of liver specimens from all groups of rats are shown. (C) The levels of mRNA of the indicated genes involved in lipogenesis were determined by real-time PCR. Each bar represents the mean ±SE of the results obtained from six rats. * P < 0.05, ** P < 0.01, *** P < 0.001.

    J Lipid Res 2011 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck.

    Immunophilins participate in SOCE activation by CN-dependent but also CN-independent signaling pathways. Fura-2 loaded platelets were suspended in HBS and subsequently incubated at 37oC for 30 min with rapamycin (500 nM). Once incubation time was over, platelets were stimulated with TG (200 nM) in a calcium free-HBS (EGTA 100 μM was added as indicated the by arrowhead) and 4 min later CaCl2 (300 µM) was added to visualized calcium entry. Changes in fura-2 fluorescence were monitored using the 340/380nm ratio and calibrated in terms of [Ca2+]c . Traces are representative of four to six independent experiments. *,**, *** represents p < 0.05, p < 0.01 and p <0.001, respect control platelets.

    Biochim Biophys Acta 2013 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck.

  • Autophagy induced by PL-0N and PL may restrict LPS-induced inflammatory responses in RAW264.7 cells. LPS induced autophagy in RAW264.7 cells. Cells were incubated with 1 mM 3-MA or 10 uM Rapamycin in the absence or presence of LPS (1 ug/mL) for 16 h. Then immunofluorescence for LC3 was visualized using a Zeiss LSM 710 confocal microscope.

    Biochem Pharmacol 2015 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck.

    Inhibition of mTOR activity may be responsible for sorafenib-induced down-regulation of survivin. H1299 cells were treated with the indicated concentration of RAD001 or Rapamycin for 48 h. Then H1299 cells were incubated with or without 5 μM sorafenib, with or without 5 μM RAD001, and with or without 2 μM rapamycin for 48 h.  The indicated protein levels were determined by Western blot analysis. β-Actin protein levels were measured as loading controls.

     

     

    Biochem Pharmacol 2011 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck.

  • Tuberc Respir Dis 2013 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck.

    Rapamycin inhibits growth-dependent TCTP induction. Cells were serum-starved for 24h and restimulated with 20% FBS for the indicated times in the presence or absence of rapamycin. The graph shows the relative TCTP signal, corrected for the loading control.

    2011 Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck.

  • 2013 Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck.

产品安全说明书

mTOR抑制剂选择性比较

生物活性

产品描述 Rapamycin (Sirolimus)是一种特定的 mTOR 抑制剂,在 HEK293细胞中,IC50 为 ~0.1 nM。
靶点
mTOR [1]
(HEK293 cells)
~0.1 nM
体外研究

Rapamycin作用于HEK293细胞,抑制内源性mTOR活性,IC50为~0.1 nM,而iRap和AP21967 作用时,IC50分别为~5 nM 和~10 nM。[1] Rapamycin处理酿酒酵母,诱导细胞周期停在G1/S期,且抑制翻译。[2] Rapamycin显著抑制T98G和U87-MG细胞活力,这种作用具有剂量依赖性,IC50分别为2 nM和 1 μM, 而对U373-MG细胞没有作用活性,IC50>25 μM。Rapamycin(100 nM) 作用于对Rapamycin敏感的U87-MG和T98G细胞,通过抑制mTOR功能,而诱导细胞周期停在G1期,也诱导自噬而不是凋亡。[6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 M3zCZmN6fG:2b4jpZ{BCe3OjeR?= M1[yWVExKG6P NFXjR4w4OiCq M4\PT2ROW09? MUPQc5RmdnSrYYTld{Bk[W2ydH;0bIVkcW5vaX7keYNm\CCleYTveI95cWOrdIm= MorkNlQ6ODB6N{O=
HT-29 NYf4ZZdRS3m2b4TvfIlkKEG|c3H5 NUXGOYdQOTBibl2= MX63NkBp Mn3qSG1UVw>? NGPRWYZRd3SnboTpZZRmeyCmaXfpeI95cW5vaX7keYNm\CCleYTveI95cWOrdIm= MYiyOFkxODh5Mx?=
HT-29 Mmi1R5l1d3SxeHnjJGF{e2G7 NHnUbnAyOCCwTR?= M1XqbVczKGh? M2LINWROW09? NEnod|FRd3SnboTpZZRmeyB3LX\seY9zd3W{YXPpcE1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>? NWTFTJlYOjR7MEC4O|M>
PC3 M4rCPGtqdmG|ZTDBd5NigQ>? MmfjNVAxKG6P NHHVSJoyKGh? Mm[2SG1UVw>? NH;ZU5hRd3SnboTsfUBqdmirYnn0d{BuXE:ULX3l[IlifGWmIGO2JJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhRDFyIH7NMi=> MYCyNVk4QDZ6Mx?=
PC3 MUXLbY5ie2ViQYPzZZk> MVixNFAhdk1? M2fCcFEhcA>? M{fhZWROW09? NVf4WVM{TG:nczDuc5QhcW6qaXLpeEBuXE:ULX3l[IlifGWmIFHreEBxcG:|cHjvdplt[XSrb36= NGD4OXkzOTl5OE[4Ny=>
PC3 M3fGcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jpd|EvPSEQvF2= MWSxJIg> NHexT3VFVVOR MV7JcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RiaIXtZY4hWEN|IHPlcIx{KHerdHigTWM2OCCxZjC8NVAhdk1? NHXRPXczOTl5OE[4Ny=>
HEK293 MmjRSpVv[3Srb36gRZN{[Xl? MYSxNFAhdk1? MoC1PEBp MX\EUXNQ MkfRTY5pcWKrdIOgWHBCNWmwZIXj[YQh\GWpcnHkZZRqd25ib3[gVIRk\DRid3n0bEBGSzVyIH;mJFUxKG6P NHLrUGIzOTV|OUOwNS=>
BT-20 MXzLbY5ie2ViQYPzZZk> NInXZ40zOCEQvF2= NIjYb2JFVVOR MnXhSI9meyCwb4SgbY5pcWKrdDDtWG9TSzJiZHXw[Y5l\W62IIDBb3QhWzR5MzDwbI9{eGixconsZZRqd25? M{K0[VIyOzV|NUWx
U937 NHnOUIVCdnSrYnHjeIVzcWGuIFHzd4F6 MkLpOVAh|ryP M3jXSlQ5KGh? M4[0U2ROW09? NWjafGdbUW6mdXPld{BidnSrYnHjeIVzcWGuIHHjeIl3cXS7IHHnZYlve3Rid3ns[EB1gXCnIFzl[4lwdmWubHGgdI5mfW2xcHjpcIEhWGirbHHk[YxxcGmjLUGgTnI{OiCrbjDVPVM4KGOnbHzz MXKyNVE1OjFyNh?=
U937 M2PteWFvfGmkYXP0[ZJq[WxiQYPzZZk> NEHyc3g2OCEQvF2= NXK0N3FEPDhiaB?= NXL1d2NoTE2VTx?= NUOzR4xZTG:nczDuc5QhcW6mdXPlJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCCPSWCgdJJwfGWrbj3k[YZq[2mnboSgUIVocW:wZXzsZUBxdmW3bX;wbIlt[SCMUkOyMVIhcW5iVUmzO{Bk\Wyucx?= MXiyNVE1OjFyNh?=
U937 MmX3RY51cWKjY4TldolidCCDc4PhfS=> Mm[1OVAh|ryP M1rSZ|Q5KGh? M{TiTmROW09? MlmxSI9meyCwb4SgbY5lfWOnIHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEBGe2OqZYLpZ4hq[SClb3zpJGhDOTBzIHnuJHU6OzdiY3XscJM> MkL2NlEyPDJzME[=
MCF-7 M4HoZmF2fG:yaHHnfUBCe3OjeR?= NYr4eWNrOzBibl2= NEHZT2Q1KGh? Moj3SG1UVw>? M1T2Smlv\HWlZYOgZZV1d3CqYXf5 NWC5V4RUOjByMkixN|Q>
U87MG NG\NUpBMcW6jc3WgRZN{[Xl? MoTINUDPxE1? M3H4XFYhcA>? MoO3SG1UVw>? M{HNb3BwfGWwdHz5JIlvcGmkaYTzJI1VV1JvbXXkbYF1\WRiU{[gdIhwe3Cqb4L5cIF1cW:w MUCxPVg1QDRyNB?=
U87MG M1nCdWtqdmG|ZTDBd5NigQ>? NWX2blFqOSEQvF2= NXzYXJo6PiCq NXfuS|FyTE2VTx?= MnX3VI91\W62bImgbY5pcWKrdIOgOGVDWDFqVEewLUBxcG:|cHjvdplt[XSrb36= NWm4ZVlYOTl6NEi0NFQ>
U87MG MX3LbY5ie2ViQYPzZZk> NH\uOowyKM7:TR?= MYi2JIg> MVPEUXNQ NFz4SJBFd2W|IH7veEBqdmirYnn0JI1VV1JvbXXkbYF1\WRiQXv0JJBpd3OyaH;yfYxifGmxbh?= M33SNFE6QDR6NEC0
U87MG M13OfGtqdmG|ZTDBd5NigQ>? NG\4d5kyKM7:TR?= MVq2JIg> MUPEUXNQ MWjEc4V{KG6xdDDpcohq[mm2IGCtOGVDWDFqVEO3M|Q3MSCyaH;zdIhwenmuYYTpc44> NFmyfowyQTh2OESwOC=>
COS7 cells expressing EGFP-HDQ74/rheb MWnBeZRweGijZ4mgRZN{[Xl? MUewMlIh|ryP MoTPNlQhcA>? NGLB[nJFVVOR MXjJcoR2[2W|IHH1eI9xcGGpeR?= M3HGVVE5OzlzOUS5
COS7 cells expressing EGFP-LC3 MV\BeZRweGijZ4mgRZN{[Xl? MnvZNE4zKM7:TR?= NVvVVIZ4OjRiaB?= MoPaSG1UVw>? MmOyTY5lfWOnczDheZRweGijZ4m= NWPVbnJrOTh|OUG5OFk>
H4 MXPGeY5kfGmxbjDBd5NigQ>? M{fZZVAvOiEQvF2= M{PjWVI1KGh? NYH5SFMxTE2VTx?= MULJcoNz\WG|ZYOgeIhmKHKjdHnvJI9nKGyrZ3j0JINp[WmwIEOgd5VjfW6rdDCyJJRwKGyrZ3j0JINp[WmwIEOgd5VjfW6rdDCxJIlvKGi3bXHuJGg1KGOnbHzz MnLINVgxOjR3OES=
HeLa NUnjU4NDTnWwY4Tpc44hSXO|YYm= NWPtfIxOOTByIH7N NXXVXldxOzZiaB?= MV3EUXNQ NYr1Z4xYUW6mdXPld{BHWkJiS{KwPVVRNCCWMkC5PGwtKFd{MUCxSkBufXSjboSteYJqeXWrdHnuR{BqdnSncnHjeIlwdg>? NUi4WGJkOTd3NkOzPFU>
HeLa NHHNT4tHfW6ldHnvckBCe3OjeR?= MVGxNFAhdk1? M37hOFM3KGh? NFTZbnRFVVOR MVLJcoR2[2W|IF\SRkBYOjFyMV[gcZV1[W62LYXibZF2cXSrblOgbY51\XKjY4Tpc44> M4C3NFE4PTZ|M{i1
HeLa M4DwSGZ2dmO2aX;uJGF{e2G7 M3vzeFExOCCwTR?= MX2zOkBp MWPEUXNQ NXv5[3k{UW6mdXPld{BHWkJvRlvCVEBkd22ybHX4JIlvfGW{YXP0bY9v NF7FeooyPzV4M{O4OS=>
SYF M2TIfWZ2dmO2aX;uJGF{e2G7 MlvQNVAxKG6P NWL1VllLOjRiaB?= MlvySG1UVw>? NVTqPGhCUW6mdXPld{BHWkJvRlvCVEBkd22ybHX4JIlvfGW{YXP0bY9v NEDHdlcyPzV4M{O4OS=>
SYF M2f2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M332VFExOCCwTR?= Mkf2NlQhcA>? M4rSWmROW09? M4POS2lv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDTXWYh[2WubIO= MnnJNVc2PjN|OEW=
HEK293T M1PJeGFvfGm4aYLhcEBCe3OjeR?= NE\ZeYcyKG6P MWG0JIQ> NH[4UHJFVVOR M1LHfmlv\HWlZYOgZY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCUNTD3bZRpKEWFNUCgc4YhOC5zIH7N NVXaTnM{OTd2OEW1NFE>
HEK293T MlPXRY51cX[rcnHsJGF{e2G7 MWixJI5O MUm0JIQ> NXnldmlNTE2VTx?= NHTFOIZKdmS3Y3XzJIFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiWESge4l1cCCHQ{WwJI9nKDBwMzDuUS=> M{m2[VE4PDh3NUCx
PBMC M2TmbmZ2dmO2aX;uJGF{e2G7 MWexJI5O M3nNPFE1KGR? MmDVSG1UVw>? MkfjVoVlfWOnczDDR3I2KGSnboPpeJk> NEPiSIUyPzR6NUWwNS=>
PBMC NH76b4dHfW6ldHnvckBCe3OjeR?= M17UVVEhdk1? NH;5T4MyPCCm M4TXO2ROW09? NEPJRYlFd2W|IH7veEBi\m[nY4SgR3hEWjRiZHXud4l1gQ>? NGLFTogyPzR6NUWwNS=>
HEK293 cells NWDveVVIU2mwYYPlJGF{e2G7 NVPPbmZTPTBibl2= NFLtc5E1PSCvaX6= M3XyXGROW09? NFv0b|FKdmirYnn0d{BuXE:UIHvpcoF{\SCjY4Tpeol1gSC5aYToJGlEPTBib3[gNE4yKG6P M3jsWlE4OzVyOUWz
Drosophila melanogaster S2 cells transfected with N-luc and C-luc NFrLcJRHfW6ldHnvckBCe3OjeR?= M2HhelExOCCwTR?= MWi0JIg> MWPEUXNQ MYHJcoR2[2W|IHz1Z4ln\XKjc3WgdJJwfGWrbjD0doFvey2|cHzpZ4lv\yCrbjDEdo9{d3CqaXzhJI1mdGGwb3fhd5RmeiCVMjDj[YxteyC2cnHud4Zm[3SnZDD3bZRpKE5vbIXjJIFv\CCFLXz1Zy=> Mmj5NVcyOjh{NkK=
Human mixed lymphocyte NGj2U4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkP5OUBvVQ>? MUXEUXNQ MWXJR|UxRTFwNjDuUU4> MVuxOlE5PTh4NR?=
Lewis rat lymph node cells M1jBemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDnOUDPxE1? M1TOb2ROW09? NXLyNnE1UUN3ME2yMlYh|ryP MlHkNVYyQDV6NkW=
cells from the thymus of normal BALB/c mice NHvXZ|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILiWXUyOCCwTR?= MX23NkBp NUDH[HM4TE2VTx?= MUXJcohq[mm2czDsfY1xcG:ycn;sbYZmemG2aX;uJEhNSUZrIIfpeIghUUN3MDDv[kA{KG6P Mn7JNVAxOjF7NEi=
MRK-nu-1 M4DqbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTBwOES1JJBO NUn0NYV2W0GQR1XS
OCUB-M NWfscnliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnlTWM2OD13LkK0JJBO MnLHV2FPT0WU
SF539 Mn7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDSSWZKSzVyPUGxMlYheE1? NXjWPJg6W0GQR1XS
ES4 M2XobGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjRb3RLUUN3ME2yNU42KHCP M1zN[3NCVkeHUh?=
RL95-2 MlPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XFWWlEPTB;MUC3JJBO NYrtSY5jW0GQR1XS
LC-2-ad MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonuTWM2OD12MkOgdG0> MnH1V2FPT0WU
Daudi MmLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnn6TWM2OD12M{SgdG0> NXzNbmxGW0GQR1XS
NTERA-S-cl-D1 M324fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGW4fHFKSzVyPUS0N{BxVQ>? Mn\TV2FPT0WU
OS-RC-2 NWfoR|BXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjoNHYxUUN3ME22OVIheE1? NGjU[otUSU6JRWK=
VA-ES-BJ MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFWwOXJKSzVyPUeyN{BxVQ>? NYDxPZNZW0GQR1XS
GR-ST M4PzPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDsOYp5UUN3ME24OFYheE1? MlvpV2FPT0WU
SW872 M2TVN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTqc3FIUUN3ME24OFYheE1? NYnGeXNIW0GQR1XS
NOS-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nxeWlEPTB;OEexJJBO MVrTRW5ITVJ?
MC116 M{TZW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvCTWM2OD17OEWgdG0> M{XSSXNCVkeHUh?=
NCI-H1355 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTFwMEGgcm0> MX3TRW5ITVJ?
RPMI-8226 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml[0TWM2OD1zLkG5JI5O MkDzV2FPT0WU
TE-15 NWD2UHpQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTFwM{[gcm0> Mor6V2FPT0WU
Ramos-2G6-4C10 MnjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX6wWGNFUUN3ME2xMlQ3KG6P NFLjXohUSU6JRWK=
KU812 NIWwb5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XqUmlEPTB;Mj6wNUBvVQ>? MV;TRW5ITVJ?
EW-1 NXzwXph{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXrfm1RUUN3ME2yMlE4KG6P NH2x[|JUSU6JRWK=
KS-1 NVzCZZVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTJwNEWgcm0> M{TZS3NCVkeHUh?=
SK-LMS-1 M4HHTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDZVoNUUUN3ME2yMlQ6KG6P NIjKN3JUSU6JRWK=
TGBC1TKB NGrVOFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LB[2lEPTB;Mj62PUBvVQ>? MYnTRW5ITVJ?
TE-6 NXHPRotNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mki4TWM2OD1{Lke3JI5O NX\DXo5xW0GQR1XS
ETK-1 M1H6d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TuOGlEPTB;Mj64NkBvVQ>? MV;TRW5ITVJ?
BE-13 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfZTWM2OD1{Lkm5JI5O NHPjWHhUSU6JRWK=
A3-KAW MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHLclBKSzVyPUKuPVkhdk1? M3HXSnNCVkeHUh?=
TE-10 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLDW2NTUUN3ME2zMlMhdk1? NF\IT2FUSU6JRWK=
DOHH-2 NHXaVmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfhTWM2OD1|LkO1JI5O MmPWV2FPT0WU
ES6 NV;TWpRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4exeGlEPTB;Mz60N{BvVQ>? Ml6xV2FPT0WU
OPM-2 NHfOfJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULEeVRrUUN3ME20MlE2KG6P NV3OdpJUW0GQR1XS
SH-4 NHiybGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvjRm9KSzVyPUSuN|Qhdk1? MonHV2FPT0WU
NB13 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjPcWZnUUN3ME20MlM3KG6P NFr1SGxUSU6JRWK=
HUTU-80 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXH1cY9xUUN3ME20MlQzKG6P NV[wXo81W0GQR1XS
CCRF-CEM NYLEc3BsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTRwOUSgcm0> MlnrV2FPT0WU
TGBC24TKB M17KSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTVwNUGgcm0> M{[yZ3NCVkeHUh?=
697 MmrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vLTmlEPTB;Nj6yPEBvVQ>? M17XdnNCVkeHUh?=
J-RT3-T3-5 M4Pkbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXe0Um5SUUN3ME22MlQ3KG6P MYXTRW5ITVJ?
KALS-1 M3fLcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3GxTGlEPTB;Nj61OkBvVQ>? M4TrNHNCVkeHUh?=
no-10 NYOwW5JXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3wXpRsUUN3ME23MlI6KG6P M1;jcXNCVkeHUh?=
SK-NEP-1 NG\IWXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fwemlEPTB;OD63PUBvVQ>? MmXkV2FPT0WU
L-540 NFTlUIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnH4TWM2OD1zMD60NkBvVQ>? M2DUbnNCVkeHUh?=
JiyoyeP-2003 NFP1UmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTFyLkm0JI5O M3LXcXNCVkeHUh?=
HH M1PBV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjiTWM2OD1zMT6zPUBvVQ>? NH2zdo1USU6JRWK=
SR MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHUTWM2OD1zMT60OUBvVQ>? MUfTRW5ITVJ?
QIMR-WIL MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37qV2lEPTB;MUGuPFUhdk1? MlK0V2FPT0WU
A4-Fuk NELFd3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTF|LkGyJI5O M1f1b3NCVkeHUh?=
CESS M4HVbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTF|LkGzJI5O M2OyUHNCVkeHUh?=
KE-37 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3VTWM2OD1zNj6wO{BvVQ>? NWfvelFZW0GQR1XS
SK-UT-1 M1X6RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDvV3N[UUN3ME2xOk45OSCwTR?= MlLpV2FPT0WU
SIG-M5 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;GV|hwUUN3ME2xO{4zPSCwTR?= NXrzdnBrW0GQR1XS
HT MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUmzNmQyUUN3ME2xO{43KG6P NIfWVphUSU6JRWK=
DEL M3SzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLyTWM2OD1zNz65PUBvVQ>? NFTEPJlUSU6JRWK=
SK-PN-DW MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1WxcGlEPTB;MkCuNlMhdk1? MU\TRW5ITVJ?
RPMI-8402 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NESx[HFKSzVyPUKxMlc4KG6P M2W0[nNCVkeHUh?=
RPMI-6666 NXLI[WFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTJ2LkSyJI5O MXnTRW5ITVJ?
NCI-H720 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2ToXGlEPTB;MkWuOFEhdk1? MUDTRW5ITVJ?
EW-16 NUDpWWVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHQfG9wUUN3ME2yOk45PyCwTR?= NHXXV3FUSU6JRWK=
BL-70 M3f3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\FTWM2OD1{OD6zPEBvVQ>? M2KxbHNCVkeHUh?=
SF126 NXyxflYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYmzd4o4UUN3ME2zNE4{QCCwTR?= NGnZU4xUSU6JRWK=
BC-1 NIfIbGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TiW2lEPTB;M{GuNlYhdk1? MnfoV2FPT0WU
MHH-PREB-1 Mn\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLG[nF4UUN3ME2zNk41PCCwTR?= MV3TRW5ITVJ?
A101D MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fpSmlEPTB;M{KuOlIhdk1? MlntV2FPT0WU
NMC-G1 M4P4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLBTWM2OD1|Mz62O{BvVQ>? MlHTV2FPT0WU
LB1047-RCC NWLPUIV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIra[o9KSzVyPUO0MlY6KG6P NUficW1pW0GQR1XS
EM-2 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPsWopKSzVyPUO4MlU{KG6P NX;KNFU{W0GQR1XS
COLO-684 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LUXWlEPTB;M{muPEBvVQ>? MojCV2FPT0WU
Becker M{Hjbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXFTWM2OD12MT6wOUBvVQ>? MUXTRW5ITVJ?
BL-41 NWDEb5BQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrtOlVKSzVyPUSzMlY3KG6P NYqw[2hLW0GQR1XS
MDA-MB-134-VI M2j3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTR2LkCyJI5O NIPpRplUSU6JRWK=
L-363 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLBVIpKSzVyPUS0Mlc{KG6P NEfR[IJUSU6JRWK=
ECC4 NWTqV|RLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTR2Lke4JI5O MkXJV2FPT0WU
A388 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PL[2lEPTB;NESuPFIhdk1? M2Dmc3NCVkeHUh?=
HEL NYnnSZl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTR7Lke5JI5O MkKzV2FPT0WU
RKO NV;Rd5pJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvSTVJKSzVyPUWwMlI6KG6P NGHxZWZUSU6JRWK=
KINGS-1 M2XCc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;IdWlEPTB;NUGuOVUhdk1? NGLvPYpUSU6JRWK=
EB-3 NY\0cIxXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzxPHQzUUN3ME21Nk43PyCwTR?= Mn3ZV2FPT0WU
ARH-77 M3rwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLveoxIUUN3ME21Nk45KG6P M3LzTXNCVkeHUh?=
GCIY MoXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVSzPVhEUUN3ME21N{41PiCwTR?= NIH6eWlUSU6JRWK=
NCI-H1304 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTV5LkKyJI5O NILBUmpUSU6JRWK=
KARPAS-299 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DlPWlEPTB;NkGuPFIhdk1? MYjTRW5ITVJ?
IA-LM MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXO1eGtvUUN3ME22PE4yOyCwTR?= MoP6V2FPT0WU
GI-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjuTFh1UUN3ME23NE4{QSCwTR?= MlW1V2FPT0WU
TE-11 NFn4V41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DvdGlEPTB;N{euNVchdk1? MlThV2FPT0WU
LS-411N MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTd5LkW3JI5O NUjVfpZmW0GQR1XS
no-11 Mk\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fQN2lEPTB;OEOuNlQhdk1? NUn0WnBPW0GQR1XS
MV-4-11 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjLTWM2OD16Mz63N{BvVQ>? MmfKV2FPT0WU
BV-173 NXSy[Jd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LIOGlEPTB;OEOuPVchdk1? MkL0V2FPT0WU
CMK NIDscIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XpemlEPTB;OESuNVYhdk1? M3TqWXNCVkeHUh?=
LC4-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nYemlEPTB;OE[uO|Ihdk1? MWnTRW5ITVJ?
COR-L279 NEfZWYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LoVGlEPTB;OEeuNlUhdk1? MUXTRW5ITVJ?
NCI-H209 NUCxWpBFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;MV29oUUN3ME24O{41OSCwTR?= M2fzV3NCVkeHUh?=
Raji NUPSU|hXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXWRnM4UUN3ME24PU44OiCwTR?= NEToNXBUSU6JRWK=
LB996-RCC Mm\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTl|LkSzJI5O MXTTRW5ITVJ?
NCI-H526 M2DNNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHGdGlsUUN3ME25N{42QSCwTR?= Ml;MV2FPT0WU
KGN M2PWdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTl4LkK5JI5O M3G5VHNCVkeHUh?=
MOLT-4 NYLSXmppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\VW2lEPTB;OU[uO|khdk1? Moj6V2FPT0WU
PF-382 MoPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33kfGlEPTB;OU[uO|khdk1? MV\TRW5ITVJ?
BC-3 M3nX[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nIWWlEPTB;OUmuNVghdk1? MW\TRW5ITVJ?
KARPAS-422 NV\HRXc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHDUlhKSzVyPUGwNk4xQSCwTR?= M2TPWHNCVkeHUh?=
SBC-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\hWnRKSzVyPUGwO{44PSCwTR?= MnrFV2FPT0WU
LC-1F M2fhO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MomzTWM2OD1zMEiuNFUhdk1? MUjTRW5ITVJ?
GB-1 MortS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnFU2pKSzVyPUGwPU4xOiCwTR?= NEPvSXlUSU6JRWK=
SNB75 NGLmWI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\pfWlEPTB;MUG5MlY6KG6P MYXTRW5ITVJ?
BB65-RCC NXXwNo4zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33wPGlEPTB;MUG5Mlk{KG6P NXXPd3hnW0GQR1XS
NCI-N87 NFK1RnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XY[mlEPTB;MUKxMlk5KG6P NEHPTYJUSU6JRWK=
IST-MEL1 NX7F[JBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1mxXGlEPTB;MUKyMlM5KG6P MYjTRW5ITVJ?
HOP-62 NGLUXVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTF{Nj64PUBvVQ>? MoPOV2FPT0WU
ACN NWrVbFFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPKXYJlUUN3ME2xOFYvPzVibl2= MkTMV2FPT0WU
DMS-114 MlT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTF3MD62O{BvVQ>? M1jZRnNCVkeHUh?=
MLMA M3\SXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{foNWlEPTB;MUW5Mlg5KG6P M{\4OHNCVkeHUh?=
HT-144 NXHhVllZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXrTWM2OD1zNkWuOFMhdk1? M2DONXNCVkeHUh?=
C2BBe1 NVH3cmV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULue|drUUN3ME2xOlcvPzZibl2= M3G3[XNCVkeHUh?=
L-428 M4XROmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvzO3hGUUN3ME2xO|cvPyCwTR?= NVG1XmxPW0GQR1XS
DU-4475 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTF6Nz62PEBvVQ>? NVraZ3FnW0GQR1XS
CP67-MEL MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTF7OT6zPEBvVQ>? M2HqeHNCVkeHUh?=
MEG-01 MnfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlniTWM2OD1{MEGuPVYhdk1? NHLhR|JUSU6JRWK=
IST-SL2 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHPSINEUUN3ME2yNFgvPjNibl2= NGDwZ21USU6JRWK=
ES8 NYDPN25ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTJ{NT65OEBvVQ>? NWe4Wo5HW0GQR1XS
COLO-800 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnpV3NKSzVyPUKzOU4zQCCwTR?= MmXrV2FPT0WU
MFH-ino MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTJ|NT64OEBvVQ>? MXrTRW5ITVJ?
OVCAR-4 M3\0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmf3TWM2OD1{M{euNlQhdk1? M3f3THNCVkeHUh?=
PSN1 NFftOXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\QN2lEPTB;MkSyMlcyKG6P MVfTRW5ITVJ?
EW-12 MnPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjlXm9KSzVyPUK0N{4yKG6P NF;ZOXJUSU6JRWK=
HCC1599 NVHnbJEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWqySIZiUUN3ME2yOlEvPDdibl2= NFrZOpBUSU6JRWK=
SJSA-1 M4DkNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX[xdZgxUUN3ME2yO|EvPDZibl2= MWfTRW5ITVJ?
ST486 NXX5e2FRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\McWlEPTB;Mkm2MlE1KG6P MUXTRW5ITVJ?
NOMO-1 MnjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;XXI9IUUN3ME2zNFAvOjFibl2= NFHEbYZUSU6JRWK=
MN-60 NFvhNFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDIdmR1UUN3ME2zNFUvOzJibl2= NVrycpN[W0GQR1XS
HCC1187 MmPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH2ydGRKSzVyPUOwO{4zPSCwTR?= NUi0UmhsW0GQR1XS
SW982 NX3s[2s6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrjcHlKSzVyPUOxOE44PSCwTR?= M4XWOnNCVkeHUh?=
LB647-SCLC MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjscIhWUUN3ME2zNlgvPzFibl2= MV7TRW5ITVJ?
HC-1 Mm\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\EUGFKSzVyPUOzOU42KG6P MUfTRW5ITVJ?
EHEB Mn;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDNT|FxUUN3ME2zN|cvPTJibl2= MUfTRW5ITVJ?
TUR NWKwUHpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHe3W2dKSzVyPUO2N{46PSCwTR?= M3LjNHNCVkeHUh?=
LU-139 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jjeGlEPTB;M{e4MlAzKG6P MlrqV2FPT0WU
NB1 NFrvTGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvRVm1KSzVyPUO4OE41PSCwTR?= Mm\QV2FPT0WU
BB30-HNC M1;X[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\MTWM2OD1|OEiuN|Ihdk1? NGH6N|JUSU6JRWK=
HAL-01 NYP6fphrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkGxTWM2OD1|OEmuNlYhdk1? MlPnV2FPT0WU
K5 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTRzMT6zO{BvVQ>? M4HYdXNCVkeHUh?=
MZ2-MEL MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vsOmlEPTB;NEGzMlY1KG6P MWjTRW5ITVJ?
RXF393 NHHrWolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYP2THlJUUN3ME20NVYvPDVibl2= M1Lh[XNCVkeHUh?=
NCI-H1648 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M16ycmlEPTB;NEG3MlU{KG6P NEe5VFBUSU6JRWK=
TE-12 MnvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPlTVZUUUN3ME20N|QvOjZibl2= MmXMV2FPT0WU
EoL-1- NY\3[mNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrxe2FYUUN3ME20N|cvQThibl2= NYXuWpZrW0GQR1XS
JAR MmLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1T0UWlEPTB;NEO4MlYzKG6P M2fhdHNCVkeHUh?=
DSH1 NEDIUGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPVSI9KSzVyPUS1PE46OSCwTR?= MXnTRW5ITVJ?
NCI-H187 NF3BNGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fTfWlEPTB;NE[yMlgyKG6P Mnq1V2FPT0WU
HCE-4 M4nqbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGn3SnVKSzVyPUS3O{43PiCwTR?= NEewUIpUSU6JRWK=
8-MG-BA NYXmVXB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\VO4FKSzVyPUW4NU42OiCwTR?= MWDTRW5ITVJ?
KLE NVr1VY85T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTV6NT6yJI5O MUTTRW5ITVJ?
KNS-42 NYDRTllNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2POZmlEPTB;NUi2MlgyKG6P NYDIOpVXW0GQR1XS
MSTO-211H M{TuZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmqxTWM2OD14MEmuO|Qhdk1? MkPYV2FPT0WU
GDM-1 NH2zZY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHR[2VXUUN3ME22NVQvODlibl2= MWrTRW5ITVJ?
TE-1 M{\KW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzVSGRKSzVyPU[0Ok4yOiCwTR?= NXHoeoZHW0GQR1XS
BT-474 MlfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTzXIhKSzVyPU[0O{4xPiCwTR?= MnHnV2FPT0WU
KARPAS-45 M4nNO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXO2V3U{UUN3ME22OFcvPiCwTR?= M37jXnNCVkeHUh?=
MOLT-16 MmLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPNZY1uUUN3ME22OFcvQTNibl2= NVvPTZc4W0GQR1XS
KURAMOCHI M2q3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jlSWlEPTB;NkW3MlUyKG6P NI\MWFlUSU6JRWK=
K-562 M4rOR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITzcHVKSzVyPU[2PU42OSCwTR?= MWPTRW5ITVJ?
EKVX M1Huemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHWzelBKSzVyPU[3Nk44OSCwTR?= NHH2SoZUSU6JRWK=
GAK MlflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTZ5NT6zJI5O NXTVepF[W0GQR1XS
NCI-SNU-5 NIq4dVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\SdWlEPTB;NkmwMlAyKG6P Mm\VV2FPT0WU
NCI-H2126 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonTTWM2OD15Mk[uPFchdk1? NX7iVop5W0GQR1XS
CTV-1 NF3nS2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPUTWM2OD15NESuPUBvVQ>? NFHsUIRUSU6JRWK=
SW962 NWr1doQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\TPGlEPTB;N{S4MlQ1KG6P NFfCfnJUSU6JRWK=
MONO-MAC-6 MoPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTd3Nj65N{BvVQ>? M36zUnNCVkeHUh?=
NCI-H748 NUmyelZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\w[5FKSzVyPUe1PE46QSCwTR?= M163WHNCVkeHUh?=
NCI-H524 M1zUdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTBOlRKSzVyPUe4NE44OyCwTR?= MVLTRW5ITVJ?
LS-123 NES2S4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfvOHlKSzVyPUe5OU43QSCwTR?= M1jJfnNCVkeHUh?=
NB7 M1\5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn74TWM2OD16MUSuNVQhdk1? MWfTRW5ITVJ?
LS-1034 Ml7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWGzVoRFUUN3ME24NlgvQThibl2= MUjTRW5ITVJ?
TE-5 M3PNRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEC3dZFKSzVyPUi4N{42PiCwTR?= NUDpW2txW0GQR1XS
A704 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fQSGlEPTB;OEm5MlE2KG6P M{jXSnNCVkeHUh?=
TK10 NHnHPXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPRTWM2OD17MU[uNFMhdk1? NFHqcGtUSU6JRWK=
NCI-H345 NFHjc21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFO0b4dKSzVyPUm0N{4zOiCwTR?= MYDTRW5ITVJ?
CGTH-W-1 NVi4TG95T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnKwTWM2OD17NEiuNVMhdk1? MXjTRW5ITVJ?
NCI-H510A NV3HU4FFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTl6NT6xNkBvVQ>? NUfJfJZWW0GQR1XS
NCI-H1963 NVfLbFhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDyd3VKSzVyPUGuNFMzQTJizszN MYDTRW5ITVJ?
SCC-3 MmS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITsV2VKSzVyPUGuNFM1OTRizszN NWrSeHFRW0GQR1XS
EW-11 NFHRe29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLnfYdKSzVyPUGuNFg4PDNizszN Moj3V2FPT0WU
CPC-N NHjWU4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIT1SlVKSzVyPUGuNFg5KM7:TR?= M1WxSHNCVkeHUh?=
NCI-H1417 Mn7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTFwMUKyOkDPxE1? MlrFV2FPT0WU
DG-75 M2\SSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXsTWM2OD1zLkG2Nlg2KM7:TR?= NYfxNJh5W0GQR1XS
HD-MY-Z M2nqSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTFwMU[0NVYh|ryP NY\jS3NXW0GQR1XS
ATN-1 Ml;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPvdXZKSzVyPUGuNlYzODlizszN NWG2PHNSW0GQR1XS
KM-H2 M4D6RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTFwMk[0NFgh|ryP MXHTRW5ITVJ?
NCI-H2081 NF;TcmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;KNnZEUUN3ME2xMlI3PjN5IN88US=> NIT2eFBUSU6JRWK=
HL-60 MmTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jZNmlEPTB;MT6yOlk2QSEQvF2= MmLPV2FPT0WU
DB NEPzNHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\oTY9JUUN3ME2xMlI4OjR{IN88US=> MnTBV2FPT0WU
NCI-H1522 Mo\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XGOGlEPTB;MT6yPFg5PyEQvF2= NEjZdIxUSU6JRWK=
AM-38 M4PvUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTFwM{C3NkDPxE1? Mn\JV2FPT0WU
NCI-H446 Mli4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXZTWM2OD1zLkOyNVIyKM7:TR?= MoLpV2FPT0WU
SU-DHL-1 NET5V5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTFwM{K4NFEh|ryP NYLBcIZvW0GQR1XS
NH-12 NGXKNolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILXOnpKSzVyPUGuN|Y{PzRizszN MVzTRW5ITVJ?
DMS-79 MnPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlftTWM2OD1zLkO2PFY3KM7:TR?= MVvTRW5ITVJ?
NCI-H716 NY\FRlVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTFwM{i5PFYh|ryP NWO4fXRYW0GQR1XS
ML-2 NEjPPVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDnOIZnUUN3ME2xMlQyPTJ7IN88US=> NWLMT5NqW0GQR1XS
NB10 M{TIfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrIWo9KSzVyPUGuOFY3OzJizszN MYPTRW5ITVJ?
ONS-76 MlSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH2yb4hKSzVyPUGuOVM2PjlizszN M336enNCVkeHUh?=
LOUCY MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDURXAzUUN3ME2xMlU1PjV5IN88US=> MVrTRW5ITVJ?
SCLC-21H NUHYeGlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTLTWM2OD1zLkW4OVgzKM7:TR?= MUHTRW5ITVJ?
TGW MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TrU2lEPTB;MT62N|k4PSEQvF2= MnHPV2FPT0WU
LXF-289 MljjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHlUog1UUN3ME2xMlc{OjZ6IN88US=> MoOzV2FPT0WU
BB49-HNC Mk[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTFwN{O1PFYh|ryP NF3KcYhUSU6JRWK=
NCI-H747 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFT5[WxKSzVyPUGuO|U{PDZizszN NH:w[oVUSU6JRWK=
LU-165 NFTjZ5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzrVmZKSzVyPUGuPFQ6QDZizszN MV3TRW5ITVJ?
OMC-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkm5TWM2OD1zLkm1NFY3KM7:TR?= NXrH[XpTW0GQR1XS
RCC10RGB MoLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTFwOUW4NVch|ryP MUTTRW5ITVJ?
SW684 NFfheGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3tTWM2OD1zLkm2NFk6KM7:TR?= Ml7xV2FPT0WU
TE-8 MmjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmr0TWM2OD1{LkC1OVU6KM7:TR?= NEDLTnNUSU6JRWK=
SK-N-DZ MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rTd2lEPTB;Mj6xN|I4PCEQvF2= M{LSb3NCVkeHUh?=
EVSA-T MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;tXIZKSzVyPUKuNVc{OTVizszN NU\GS5VxW0GQR1XS
KASUMI-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvLS41sUUN3ME2yMlE5QDF3IN88US=> MXLTRW5ITVJ?
NKM-1 MofFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1THbGlEPTB;Mj6yOVQ4OiEQvF2= NHGxeVhUSU6JRWK=
CAL-148 M1nifWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPlNI1KSzVyPUKuN|M3OTRizszN M3TxZ3NCVkeHUh?=
NCI-H64 MoPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\3TWM2OD1{LkO0NlMzKM7:TR?= NXr0ZlVKW0GQR1XS
KNS-81-FD NUe3cWNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17nUWlEPTB;Mj6zOlYzKM7:TR?= NYPGR48{W0GQR1XS
KM12 NEDGdXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHPWXVSUUN3ME2yMlQxQDN7IN88US=> M{fQTHNCVkeHUh?=
SW954 NWq3cpltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTJwNEe3O|kh|ryP NW\xNG56W0GQR1XS
NCI-H1395 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULuWWpZUUN3ME2yMlUzPjR3IN88US=> M{[4NXNCVkeHUh?=
DJM-1 MorWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jJbWlEPTB;Mj62NFY{KM7:TR?= MWHTRW5ITVJ?
COLO-668 MkG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDPTWM2OD1{LkiyOlk2KM7:TR?= MmXHV2FPT0WU
NCI-H1436 MoHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPkbIZKSzVyPUKuPFU3OTVizszN NGHzNZlUSU6JRWK=
LB2241-RCC M{CyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTJwOE[4N|kh|ryP M3;1THNCVkeHUh?=
GT3TKB M{i2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPkdJhCUUN3ME2yMlg6ODV3IN88US=> NYX5UYN5W0GQR1XS
COLO-824 NVHu[HRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjzdmlKSzVyPUKuPFk4PjhizszN M1y5WnNCVkeHUh?=
ES1 NGrTT2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLuUWhuUUN3ME2yMlg6QDd7IN88US=> NH3aO2RUSU6JRWK=
LB771-HNC M{\IZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTJwOUC5OFYh|ryP NXrjb2JwW0GQR1XS
GI-ME-N NWTTeFNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTNwMEC5NFQh|ryP NVLlfJVTW0GQR1XS
NALM-6 M2T3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTNwMEC5N|Mh|ryP NF[0foFUSU6JRWK=
LU-134-A M2fpS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\sWGlEPTB;Mz6wOVQzPSEQvF2= NYSxd3VrW0GQR1XS
DMS-153 NHfkRlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PGfGlEPTB;Mz6wOVgzPCEQvF2= M{Lm[3NCVkeHUh?=
MZ1-PC NHK3OHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXidFVKSzVyPUOuNFkxPzhizszN NV7hXpRtW0GQR1XS
NCI-H1155 Ml;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTNwMUG2NUDPxE1? MmW1V2FPT0WU
CAS-1 NXXidoNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTNwMUO3NFch|ryP MXTTRW5ITVJ?
D-502MG NEHKd41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfDc5BKSzVyPUOuNVQ{QSEQvF2= M4D4N3NCVkeHUh?=
NCI-H2141 NH;VXFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LONWlEPTB;Mz6xO|Q2OiEQvF2= MXPTRW5ITVJ?
NB6 NWHWSnoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTNwMUiyOVkh|ryP MofsV2FPT0WU
NCCIT NYPoboRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmi0TWM2OD1|LkKxPFA6KM7:TR?= Mmj0V2FPT0WU
NB69 M1e4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrPdGVIUUN3ME2zMlMyQDlzIN88US=> NEPUXWZUSU6JRWK=
JVM-2 MkfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXKSXl2UUN3ME2zMlM3PDN|IN88US=> NIqwR2ZUSU6JRWK=
K052 NFv0dIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXU[I1KSzVyPUOuN|c6PjhizszN MkXiV2FPT0WU
HCC2157 Mo[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmntTWM2OD1|LkWzNlI5KM7:TR?= MlHZV2FPT0WU
KMOE-2 MnjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfl[Y9KSzVyPUOuOVQzPDJizszN NFK1PVJUSU6JRWK=
SF268 M4r4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTNwN{G1OVQh|ryP NFf0e3VUSU6JRWK=
CHP-126 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXyze5pyUUN3ME2zMlc3PDV6IN88US=> NIPWfZFUSU6JRWK=
CP66-MEL M1O4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTNwN{mwPVQh|ryP M1;5S3NCVkeHUh?=
NCI-H69 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjEWmZKSzVyPUSuNFE6OzZizszN NFi2TIhUSU6JRWK=
A253 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDWNFZKSzVyPUSuNFIyODFizszN NVPkOJZFW0GQR1XS
NB14 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jTe2lEPTB;ND6xNFQ4QSEQvF2= MUXTRW5ITVJ?
NCI-H1694 M3zXb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrWeHV1UUN3ME20MlE{OTF{IN88US=> MoSyV2FPT0WU
NCI-H2196 NV\0d5M{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoG3TWM2OD12LkG3NVY6KM7:TR?= NXX5[ol2W0GQR1XS
TE-9 NILJbppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTRwMUe1PFIh|ryP MV7TRW5ITVJ?
D-283MED M3zLdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2CwU2lEPTB;ND6xPFg1KM7:TR?= NWrvdo5PW0GQR1XS
OCI-AML2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3G4emlEPTB;ND6xPVQ5QSEQvF2= NGDUfHNUSU6JRWK=
D-263MG MlT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHsSlBKSzVyPUSuNlI6PjFizszN NV73OJNIW0GQR1XS
MPP-89 NH;EWpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTRwMkezNFQh|ryP MoHDV2FPT0WU
LAMA-84 NGrBOldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPJTWM2OD12LkOwOFIyKM7:TR?= NF3hfphUSU6JRWK=
LB373-MEL-D MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXzTotKSzVyPUSuN|Y4QDlizszN MnPIV2FPT0WU
UACC-257 NVe0e|hbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHJfmNKSzVyPUSuN|k2OzRizszN MVrTRW5ITVJ?
MC-CAR M4ntbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1joO2lEPTB;ND60N|k6KM7:TR?= MV\TRW5ITVJ?
COLO-320-HSR MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjnWIhKSzVyPUSuOFQ1OjdizszN M2i1O3NCVkeHUh?=
P30-OHK MmfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnhZWV1UUN3ME20MlY3PThzIN88US=> NEDrW3ZUSU6JRWK=
UACC-812 M37zTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3:5WmlEPTB;ND62PVE3OSEQvF2= NV3acXlkW0GQR1XS
CTB-1 Mk\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfaTWM2OD12LkexOVU2KM7:TR?= NGnue2FUSU6JRWK=
ALL-PO M{HFNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PPcmlEPTB;ND64OFA4PyEQvF2= M2\GZ3NCVkeHUh?=
SK-MEL-2 NEnKToRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfhUo9KSzVyPUSuPFY6PTVizszN MlPJV2FPT0WU
TC-YIK MnznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHuV2psUUN3ME20Mlk4QTR{IN88US=> MXfTRW5ITVJ?
NCI-H1882 M{L0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jqbWlEPTB;NT6wNlAxOSEQvF2= MUHTRW5ITVJ?
MHH-CALL-2 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTVwMEWwOFIh|ryP M2C5OHNCVkeHUh?=
U-87-MG NFnTdmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljmTWM2OD13LkC5OFY3KM7:TR?= M3[4WXNCVkeHUh?=
NCI-H1092 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\R[mlEPTB;NT6yOlU2PSEQvF2= NEfQOZRUSU6JRWK=
TE-441-T M1O3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfoTWM2OD13LkK3PFIh|ryP M2H4b3NCVkeHUh?=
SK-MEL-1 M2jWWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlz5TWM2OD13LkK5NFQ1KM7:TR?= NHfSNIRUSU6JRWK=
EW-22 MkLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;hXHhOUUN3ME21MlI6PDZ4IN88US=> M{LDdHNCVkeHUh?=
MZ7-mel NYLrcVVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHG4e|FKSzVyPUWuOFA3QTFizszN M1nLT3NCVkeHUh?=
LP-1 NXPvPWNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrpfWV1UUN3ME21MlQyOjlzIN88US=> MofsV2FPT0WU
NCI-SNU-16 M{jnd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TNNmlEPTB;NT62OFA4PCEQvF2= M2fTc3NCVkeHUh?=
LU-65 MnfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTVwN{[zO|Mh|ryP MVHTRW5ITVJ?
CW-2 MkSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrOeJVCUUN3ME21Mlg2QTV7IN88US=> MmH3V2FPT0WU
WSU-NHL NGPkWmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TBdmlEPTB;NT65OVE4PCEQvF2= NXnYbW0zW0GQR1XS
IST-MES1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Gxc2lEPTB;NT65OVQ1OyEQvF2= MmLWV2FPT0WU
U-266 M2TRPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTVwOUiyNFIh|ryP M{ntfnNCVkeHUh?=
TALL-1 M3q3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTZwMUS2PFgh|ryP NEW3NFJUSU6JRWK=
Calu-6 M2\PTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnVTWM2OD14LkG1N|E3KM7:TR?= NFnQflVUSU6JRWK=
MMAC-SF NIT2NINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfBWZJKSzVyPU[uNVg2PTZizszN M3frUHNCVkeHUh?=
NCI-H82 Mn\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\MUWlEPTB;Nj6yNFQ5QSEQvF2= NIm1N3lUSU6JRWK=
RS4-11 M4\xcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3L4OGlEPTB;Nj6yOVg6PyEQvF2= M2n0XnNCVkeHUh?=
SNU-C2B Mkf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTVTWM2OD14LkSwPVY6KM7:TR?= Mn3QV2FPT0WU
BOKU M3PUe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDmTWM2OD14LkS3OVk4KM7:TR?= M3;SfXNCVkeHUh?=
C8166 M3:1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnHTWM2OD14LkW1PVEzKM7:TR?= M4TuNXNCVkeHUh?=
D-247MG MonKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYS2bXBWUUN3ME23MlA1OzR5IN88US=> M2\Z[nNCVkeHUh?=
EW-18 M4\DUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PMO2lEPTB;Nz6wO|I6OiEQvF2= M{[x[XNCVkeHUh?=
KG-1 MlnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILQNHlKSzVyPUeuOlI4OzhizszN NWDWVHVqW0GQR1XS
REH M1vC[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XSWGlEPTB;Nz62PFExQSEQvF2= NH7QXYtUSU6JRWK=
U-698-M MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnhTWM2OD15Lki0N|E2KM7:TR?= NIGxfG5USU6JRWK=
KP-N-RT-BM-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTdwOUOwNlkh|ryP NYDyRXBlW0GQR1XS
MS-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PVUmlEPTB;Nz65OlA1OSEQvF2= NYrOTpZWW0GQR1XS
SNU-C1 M2L2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XtNmlEPTB;Nz65PFE6OiEQvF2= MXXTRW5ITVJ?
SK-MM-2 NUnjNm1TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XaUGlEPTB;OD6yOlA3PSEQvF2= MXrTRW5ITVJ?
LAN-6 MkWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jkcWlEPTB;OD6zNFAxOSEQvF2= MljnV2FPT0WU
NEC8 NY\KUJBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmW2TWM2OD16LkOwOlkyKM7:TR?= Mnm5V2FPT0WU
NCI-H1770 MmezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXT6d4cyUUN3ME24MlM5ODB{IN88US=> NWraeJluW0GQR1XS
D-336MG M{PaZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRThwNECxNVYh|ryP NV60OI9EW0GQR1XS
COLO-829 Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPyPXJ4UUN3ME24MlQ5QDd7IN88US=> NU[zV|dZW0GQR1XS
LS-513 M{n4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvkPG1KSzVyPUiuOVk2QTlizszN M1vjdXNCVkeHUh?=
YT M4Tuc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\pPWlEPTB;OD62NlQzPyEQvF2= MUfTRW5ITVJ?
EW-24 M1HLOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLaNmR{UUN3ME24Mlc3PTRizszN MVLTRW5ITVJ?
IST-SL1 M4TtZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\B[nRKSzVyPUiuPFY2PDNizszN MnvkV2FPT0WU
CA46 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWr2VVJNUUN3ME24Mlk2ODl6IN88US=> NV3oflR7W0GQR1XS
NCI-H1838 MlTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PIbGlEPTB;OD65PFYxOiEQvF2= MlHpV2FPT0WU
NCI-H719 NUTSW4JNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETjbpBKSzVyPUmuNlUzPzlizszN NW\yWJVMW0GQR1XS
HCE-T NEXYZ4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXoZYZKSzVyPUmuN|A5PTFizszN MYDTRW5ITVJ?
A498 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYK2SXhCUUN3ME25MlM3OTJ2IN88US=> MWPTRW5ITVJ?
LB831-BLC Mk\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTlwN{[1NlEh|ryP NXe2XY5PW0GQR1XS
SKM-1 NUPCSW9QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\xNlRKSzVyPUmuPFU6PjNizszN MWXTRW5ITVJ?
THP-1 NIDNVZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLqNoJKSzVyPUmuPVY6OThizszN NGrwS2VUSU6JRWK=
SHP-77 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPReJdKSzVyPUGwMlQxPyEQvF2= NWfKSHdwW0GQR1XS
EW-3 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF:zT41KSzVyPUGwMlYzQDlizszN M2rWb3NCVkeHUh?=
KY821 M3vtWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HZZWlEPTB;MUCuO|Y{KM7:TR?= Mlq5V2FPT0WU
NCI-SNU-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPFTWM2OD1zMT6wNlE4KM7:TR?= NFXFc|BUSU6JRWK=
HCC2218 NXPxVpVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjXOFlCUUN3ME2xNU4{QTh4IN88US=> NXf0cZVPW0GQR1XS
IM-9 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorKTWM2OD1zMT61NVA3KM7:TR?= MlnkV2FPT0WU
NCI-H889 MkmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fjRmlEPTB;MUGuOVMyOyEQvF2= NF3JU45USU6JRWK=
HDLM-2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXPd2RKSzVyPUGyMlQyPTlizszN MUDTRW5ITVJ?
LB2518-MEL Mne0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvVcIpmUUN3ME2xNk43QDF3IN88US=> MnzqV2FPT0WU
NCI-H23 NWX3dGR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XHdWlEPTB;MUOuNlQzPSEQvF2= NXzRZphkW0GQR1XS
NB17 M3vSV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfhclZkUUN3ME2xN{41PTd7IN88US=> MmH3V2FPT0WU
NCI-H322M NUiwTpZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTF2LkSwOlgh|ryP MnT5V2FPT0WU
SUP-T1 M4\WfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFiwbGpKSzVyPUG0MlQyOyEQvF2= MULTRW5ITVJ?
ES3 MnXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rHNmlEPTB;MUWuNFcxOyEQvF2= NH:5NlVUSU6JRWK=
ES5 NFfTd25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\QZWlEPTB;MUWuNFc5PyEQvF2= NY\sbpNKW0GQR1XS
NCI-H1650 MnHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTF3LkS5O|kh|ryP NWK5ZW5pW0GQR1XS
NCI-H226 NGXaOolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3e5[GlEPTB;MUWuPFc3QCEQvF2= MYHTRW5ITVJ?
COR-L88 M17Lcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4e2eWlEPTB;MU[uN|E1KM7:TR?= M3fxZXNCVkeHUh?=
SCC-15 NYT5OoF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLH[4xKSzVyPUG2MlM5PjlizszN NH\5[5lUSU6JRWK=
GOTO MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvHbmlIUUN3ME2xOk41Pzl|IN88US=> M1\M[nNCVkeHUh?=
SIMA NICxS4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjRcGxKSzVyPUG2MlQ5ODJizszN NYnQWHFqW0GQR1XS
NCI-H1299 NX\xRWZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfCU451UUN3ME2xO{4yPTlzIN88US=> NYHXcm9HW0GQR1XS
NCI-H1581 NGDEeYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\rTWM2OD1zNz60NlE6KM7:TR?= MlLZV2FPT0WU
MHH-NB-11 NEPzZY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjGTWM2OD1zNz65Olg{KM7:TR?= Ml\WV2FPT0WU
MFM-223 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTsTWM2OD1zOD6wOVM5KM7:TR?= NHTicWlUSU6JRWK=
ES7 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfwTYFFUUN3ME2xPE42PDNzIN88US=> NEntOVRUSU6JRWK=
JVM-3 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPxTWM2OD1zOD63NVch|ryP NXHtRpd4W0GQR1XS
RL MmTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3vOo9[UUN3ME2yNE4{QDhizszN M{TPZXNCVkeHUh?=
EC-GI-10 NUi2UVVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTJzLkKwOFEh|ryP NWH1U3Y6W0GQR1XS
LNCaP-Clone-FGC NVnn[ZpLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3pN29KSzVyPUKxMlY4PjhizszN NF;seIdUSU6JRWK=
IMR-5 NGLxeotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTJzLki0PVQh|ryP NGjlSoRUSU6JRWK=
KP-N-YS M2fxNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjPcFhWUUN3ME2yNU45PzVizszN MUDTRW5ITVJ?
Mo-T MlTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXJVmJlUUN3ME2yNk4zOTh3IN88US=> MnfPV2FPT0WU
NCI-H128 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTJ|LkW4OVMh|ryP NF\Z[XlUSU6JRWK=
RH-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjre3BKSzVyPUKzMlc5PjZizszN MXXTRW5ITVJ?
NCI-H2171 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnCPIhEUUN3ME2yOE4zPDh3IN88US=> MYPTRW5ITVJ?
RPMI-8866 NUjkeIxOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTJ4Lke0NkDPxE1? MX3TRW5ITVJ?
SK-N-FI MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLEXnRKSzVyPUK3MlM5OTFizszN MnvDV2FPT0WU
LOXIMVI NWPQfpNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1myRmlEPTB;MkeuPFA2OSEQvF2= M1SwOnNCVkeHUh?=
P31-FUJ MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTNzLkWzO|Qh|ryP MY\TRW5ITVJ?
KMS-12-PE MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTR7LkWzNFIh|ryP NHviNVJUSU6JRWK=

... Click to View More Cell Line Experimental Data

体内研究 在体内,Rapamycin 处理,特定阻断mTOR下游靶点,如p70S6K磷酸化和激活,和PHAS-1/4E-BP1导致的eIF4E抑制释放, 完全阻断跖肌重量和纤维尺寸的肥厚增高。[3] 短期Rapamycin处理,即使按最低剂量0.16 mg/kg处理, 强抑制p70S6K活性, 与提高的肿瘤细胞死亡和Eker肾脏肿瘤坏死相关。[4] Rapamycin作用于CT-26移植瘤模型,通过降低VEGF产量,及阻断VEGF诱导的内皮细胞信号,而抑制转移性肿瘤生长和血管新生。[5] Rapamycin每天按4 mg/kg剂量处理C6移植瘤,显著降低肿瘤生长,和肿瘤血管通透性。[7]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

mTOR激酶免疫印迹法测定:

HEK293细胞按每孔2-2.5×105个细胞接种在12孔板上,DMEM培养基上血清饥饿处理24小时。使用浓度不断增加的Rapamycin(0.05-50 nM)在 37oC下处理细胞15分钟。加入血清,终浓度为20%,在37oC下处理30分钟。细胞溶解,使用SDS-PAGE分离细胞裂解液。再溶解的蛋白转移到聚偏(二)氟乙烯膜上,使用抗p70 S6激酶Thr-389的磷酸化的一抗进行免疫印迹。使用ImageQuant 和KaleidaGraph分析数据。
细胞实验:

[6]

+ 展开
  • Cell lines: U87-MG, T98G, 和 U373-MG
  • Concentrations: 溶于DMSO,终浓度为~25 μM
  • Incubation Time: 72 小时
  • Method:

    使用不同浓度Rapamycin处理细胞72小时。为了测量细胞活力,通过胰蛋白酶化收集细胞,使用台酚蓝染色,计数每孔的存活细胞数。为了测定细胞周期, 使细胞胰蛋白酶化,与70%乙醇混合, 使用碘化丙啶染色。使用FACScan流式细胞仪和CellQuest软件分析样本DNA含量。为了测定凋亡, 细胞染色,通过末端脱氧核苷酸转移酶调节的dUTP缺口末端标记法(TUNEL)技术,使用一个ApopTag凋亡检测试剂盒对细胞进行染色。为了测定酸性囊泡细胞器(AVO)的进展,使用吖啶橙(1 μg/mL)对细胞进行染色15分钟,使用荧光显微镜检测。为了量化AVOs的进展,使用吖啶橙(1 μg/mL) 对细胞进行染色15分钟, 然后使用胰蛋白酶-EDTA使其从实验板上移除,最后使用FACScan流式细胞仪和CellQuest 软件分析。为了分析自噬过程,细胞和0.05 mM丹(磺)酰戊二胺(MDC)在37oC下温育10分钟,然后在荧光显微镜下观察。


    (Only for Reference)
动物实验:

[7]

+ 展开
  • Animal Models: 皮下接种表达VEGF-A的C6大鼠胶质瘤细胞的无胸腺Nu/Nu小鼠
  • Formulation: 溶于溶剂溶液(0.2% 羧甲基纤维素和0.25% Tween-80,溶于无菌水)
  • Dosages: ~4 mg/kg/day
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 20 mg/mL (21.87 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 914.18
化学式

C51H79NO13

CAS号 53123-88-9
稳定性 powder
in solvent
别名 AY 22989,NSC-2260804

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00977691 Active not recruiting Peripheral Blood Stem Cell Transplantation|Anemia Sickle Cell|Graft-Versus-Host Disease|Sirolimus (Rapamune )|Alemtuzumab (Campath ) National Heart Lung and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC) September 9 2009 Phase 1|Phase 2
NCT00062712 Completed Kidney Transplantation National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) June 9 2003 Phase 2
NCT02833506 Withdrawn Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Stage IIA Fallopian Tube Cancer|Stage IIA Ovarian Cancer|Stage IIB Fallopian Tube Cancer|Stage IIB Ovarian Cancer|Stage IIC Fallopian Tube Cancer|Stage IIC Ovarian Cancer|Stage IIIA Fallopian Tube Cancer|Stage IIIA Ovarian Cancer|Stage IIIA Primary Peritoneal Cancer|Stage IIIB Fallopian Tube Cancer|Stage IIIB Ovarian Cancer|Stage IIIB Primary Peritoneal Cancer|Stage IIIC Fallopian Tube Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Primary Peritoneal Cancer|Stage IV Fallopian Tube Cancer|Stage IV Ovarian Cancer|Stage IV Primary Peritoneal Cancer Roswell Park Cancer Institute|National Cancer Institute (NCI) December 8 2017 Phase 1
NCT01885689 Active not recruiting Adult Acute Lymphoblastic Leukemia in Remission|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Adult Acute Myeloid Leukemia in Remission|Myelodysplastic Syndrome|Secondary Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia|Therapy-Related Myelodysplastic Syndrome City of Hope Medical Center|National Cancer Institute (NCI) January 8 2014 Phase 2
NCT01869114 Recruiting Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|de Novo Myelodysplastic Syndromes|Myelodysplastic Syndrome With Isolated Del(5q)|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Myeloid Leukemia Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University July 8 2013 Phase 2
NCT01363752 Completed Kidney Transplantation Astellas Pharma Inc March 8 2011 Phase 4

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

相关mTOR产品

Tags: 购买Rapamycin (Sirolimus) | Rapamycin (Sirolimus)供应商 | 采购Rapamycin (Sirolimus) | Rapamycin (Sirolimus)价格 | Rapamycin (Sirolimus)生产 | 订购Rapamycin (Sirolimus) | Rapamycin (Sirolimus)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID